To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.

The goal of this clinical trial is to evaluate the safety and feasibility of a combined surgical and chemotherapy approach (pancreatectomy with cytoreductive surgery and HIPEC) in patients aged 18 and older with pancreatic ductal adenocarcinoma and synchronous peritoneal metastases. The main questions it aims to answer are: Is the 90-day mortality rate for this intensive combined procedure lower than 5%? What are the postoperative morbidity and complication rates (as measured by the Clavien-Dindo classification) for these patients? How does this treatment impact the patient's quality of life

Trial Details

NCT ID
NCT07493421
Phase
NA
Sponsor
Unidade Local de Saúde São João
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Pancreatectomy
  • Complete Cytoreduction
  • Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Locations (sample)
  • Shanghai, shangaiShanghai Municipality, China|31.22222,121.45806
  • Lisbon, Lisbon District, Portugal|38.72509,-9.1498
  • Porto, Portugal|41.1485,-8.61097

Key Eligibility Criteria

  • Pancreatic adenocarcinoma
  • Histologically confirmed peritoneal metastasis
  • Excluded other sites of metastasis (except ovary)
  • PCI less than or equal to 6

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →